| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 2.45 | 11.6% | 1.7% |
| Total Income | 2.45 | 11.6% | 1.7% |
| Expenditure | 31.78 | 12.9% | 16.9% |
| PBT | — | ||
| Net Profit | -26.10 | 17.3% | 21.1% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.58 | 11.5% | 3.3% |
BioAge Labs Reports Q2 2026 Financial Results and Provides Business Updates
06 Aug 2026 · 6 Aug, 2:29 am
Summary
BioAge Labs reported its second quarter 2026 financial results, highlighting progress in its BGE-102 clinical development program. The company dosed the first participant in the QUELL-CV Phase 2 trial and plans to initiate the QUELL-DME Phase 1b/2a trial in mid-2026. Collaboration revenue remained stable at $2.4 million. The net loss for the quarter was $26.1 million, or $0.58 per share. BioAge ended the quarter with approximately $381.3 million in cash, which is expected to fund operations through 2029.
Key Highlights
- 1
BioAge Labs reported its second quarter 2026 financial results and provided business updates on August 5, 2026.
- 2
The first participant was dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102, with topline data anticipated in the second half of 2026.
- 3
A Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema, QUELL-DME, is planned to initiate in mid-2026, with results anticipated in mid-2027.
- 4
BioAge hosted an R&D Day in May 2026 featuring Phase 1 clinical data for BGE-102 and the therapeutic rationale for targeting NLRP3.
- 5
Collaboration revenue was $2.4 million for the quarter ended June 30, 2026, consistent with the prior year period.
- 6
Net loss for the quarter ended June 30, 2026, was $26.1 million, or $0.58 per share, compared to a net loss of $21.6 million, or $0.60 per share, in the prior year period.
- 7
As of June 30, 2026, BioAge had approximately $381.3 million in cash, cash equivalents, and marketable securities, sufficient to fund operations through 2029.
Management Comments
Kristen Fortney
NLRP3 sits at the apex of the inflammatory cascade that drives a range of diseases. Our Phase 1 data show that BGE-102 is a potential best-in-class NLRP3 inhibitor: a well-tolerated once-daily pill that delivered up to 98% suppression of IL-1β and brought hsCRP down to normal levels in most participants. We have dosed the first participant in QUELL-CV, our Phase 2 trial in patients with obesity and inflammation at elevated cardiovascular risk, with topline data anticipated in the second half of 2026. We also plan to start a second proof-of-concept trial this year in diabetic macular edema. These studies will test the broad potential of NLRP3 inhibition across inflammasome-driven diseases, and we are actively evaluating additional indications where this mechanism can deliver meaningful benefit. With a strong cash position, we are well positioned to advance BGE-102 across multiple opportunities and continue progressing the broader BioAge pipeline.
Informational and educational content only. Not investment advice.